Expression of Lymphoid Enhancer‐Binding Factor 1 in Cancer‐Associated Fibroblasts Mediates Tumor Growth and Transdifferentiation Toward Squamous Cell Carcinoma in Human Breast Cancer
Cancer Medicine · 2025
DOI: 10.1002/cam4.70627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Hiroya Okazaki und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Pathobiological Science and Surgery, Tokyo Dental College, Tokyo, Japan. Hauptthemen laut MEDLINE: Lymphoid Enhancer-Binding Factor 1, Cancer-Associated Fibroblasts, Carcinoma, Squamous Cell, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Juntendo University Graduate School of Medicine, Center for Genomic and Regenerative Medicine, Department of Oral Pathobiological Science and Surgery, Tokyo Dental College.
Abstract (Originalsprache)
Background
Cancer‐associated fibroblasts (CAFs) play a significant role in human breast cancer as a major stromal component. While their role in promoting cancer proliferation and malignancy through interaction with cancer cells in the tumor microenvironment is known, the exact mechanisms behind this interaction are not fully understood.
Results
Our study reveals that lymphoid enhancer‐binding factor 1 (LEF1), a central transcription factor for Wnt/β‐catenin signaling, is expressed in experimentally generated tumor‐promoting CAFs (exp‐CAFs) as well as in CAFs from breast cancer patients, particularly those with a poor prognosis. Notably, LEF1‐expressing CAFs are prevalent in the stroma of squamous cell carcinoma (SCC), an aggressive metaplastic breast cancer subtype with a limited understanding of its development. To investigate the functional importance of LEF1 expression in CAFs, we depleted LEF1 in the exp‐CAFs and subcutaneously implanted them along with breast ductal carcinoma MCF10DCIS.com cells into immunodeficient mice. Depleting LEF1 resulted in reduced xenograft tumor growth, accompanied by decreased cancer‐cell proliferation and angiogenesis in the tumors. Additionally, we observed a significant reduction in the expression of SCC markers p40 (ΔNp63) and cytokeratin 5/6 in the xenograft tumors when LEF1 was depleted in the exp‐CAFs. Furthermore, we identified 13 genes, none of which are established downstream genes of the Wnt/β‐catenin pathway, that exhibit expression patterns similar to LFE1 in our cultured fibroblasts.
Conclusion
In summary, our findings suggest that LEF1 expression contributes to the tumor‐promoting abilities of breast CAFs and that LEF1‐expressing CAFs may drive transdifferentiation toward SCC, possibly through a pathway independent of the canonical Wnt/β‐catenin signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Pathobiological Science and Surgery, Tokyo Dental College, Tokyo, Japan.
- Department of Pathology and Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Department of Molecular Pathogenesis, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Human Pathology, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Department of Medical Oncology and Cancer Center, Shiga University of Medical Science, Shiga Japan.
- Center for Advanced Medicine Against Cancer, Shiga University of Medical Science, Shiga, Japan.
ORCID-Profile: Yoshihiro Mezawa, Takehiro Yasukawa
Förderung
- Japan Society for the Promotion of Science
- Juntendo University Graduate School of Medicine, Center for Genomic and Regenerative Medicine
- Department of Oral Pathobiological Science and Surgery, Tokyo Dental College
- Subsidies for Current Expenditures to Private Institutions of Higher Education from the Promotion and Mutual Aid Corporation for Private Schools of Japan
- Promotion and Mutual Aid Corporation for Private Schools of Japan
Zitieren
APA
Okazaki, H., Mezawa, Y., Shi, Y., Sakimoto, M., Wang, Z., Ishizuka, A., Yamashita, K., Satoh, A., Koyama, Y., Fukumura, Y., Kajino, K., Takano, A., Yokose, T., Yamashita, T., Miyagi, Y., Daigo, Y., Katakura, A., Yasukawa, T., & Orimo, A. (2025). Expression of Lymphoid Enhancer‐Binding Factor 1 in Cancer‐Associated Fibroblasts Mediates Tumor Growth and Transdifferentiation Toward Squamous Cell Carcinoma in Human Breast Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70627
Vancouver
Okazaki H, Mezawa Y, Shi Y, Sakimoto M, Wang Z, Ishizuka A, et al. Expression of Lymphoid Enhancer‐Binding Factor 1 in Cancer‐Associated Fibroblasts Mediates Tumor Growth and Transdifferentiation Toward Squamous Cell Carcinoma in Human Breast Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.70627
BibTeX
@article{Okazaki2025,
author = {Okazaki, Hiroya and Mezawa, Yoshihiro and Shi, Yang and Sakimoto, Mizuki and Wang, Zixu and Ishizuka, Akane and Yamashita, Kazunari and Satoh, Asahi and Koyama, Yu and Fukumura, Yuki and Kajino, Kazunori and Takano, Atsushi and Yokose, Tomoyuki and Yamashita, Toshinari and Miyagi, Yohei and Daigo, Yataro and Katakura, Akira and Yasukawa, Takehiro and Orimo, Akira},
title = {Expression of Lymphoid Enhancer‐Binding Factor 1 in Cancer‐Associated Fibroblasts Mediates Tumor Growth and Transdifferentiation Toward Squamous Cell Carcinoma in Human Breast Cancer},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70627}
}
EUVIMED